Extrahepatic Insulin Resistance in Chronic Hepatitis C

NACompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

June 1, 2018

Study Completion Date

June 1, 2018

Conditions
Insulin Resistance
Interventions
DRUG

Ledipasvir 90 mg/Sofosbuvir 400 mg

Oral administration on one fixed dose combination tablet for 12 weeks

DRUG

Ribavirin

Oral administration of body weight-dose adjusted, 200 mg-tablets of ribavirin (1,000 mg in two administration in patients \<75 Kg of body weight, or 1,200 mg in two administrations for those \>75 Kg) for 12 weeks.

Trial Locations (1)

1211

Division of Gastroenterology and hepatology, University Hospital, Geneva

All Listed Sponsors
collaborator

Gastaldi Giacomo

UNKNOWN

collaborator

Clément Sophie

UNKNOWN

lead

University Hospital, Geneva

OTHER

NCT02760355 - Extrahepatic Insulin Resistance in Chronic Hepatitis C | Biotech Hunter | Biotech Hunter